PER® Winter Lung Cancer Conference | Conference

Dr. Chaft on the Rise of Immunotherapy in Lung Cancer

February 8th 2020

Jamie E. Chaft, MD, discusses the rise of immunotherapy in lung cancer and research with this treatment modality that is on the horizon.

Dr. Lilenbaum on PD-L1 as a Predictive Biomarker for Immunotherapy in Lung Cancer

February 8th 2020

Rogerio C. Lilenbaum, MD, discusses using PD-L1 as a predictive biomarker for immunotherapy and the search for additional biomarkers in lung cancer.

Emerging Targeted Therapies Emphasize Need for Molecular Testing in Lung Cancer

February 8th 2020

Benjamin P. Levy, MD, discusses emerging oncogenic markers in lung cancer and what impact they are poised to make on the paradigm.

Using TMB and PD-L1 Together Could Guide Immunotherapy Decisions in NSCLC

January 29th 2019

Until more biomarkers are available, the use of tumor mutational burden with PD-L1 expression could help oncologists further personalize immunotherapy choices for patients with non–small cell lung cancer.

Socinski Says Immunotherapy, Targeted Therapy Have Altered Outlook in NSCLC

January 29th 2019

Mark A. Socinski, MD, provides an overview of treatment advances in the lung cancer landscape, and highlights where much-needed work still remains.

Expert Stresses Significance of Durvalumab Success in Stage III NSCLC

January 28th 2019

Findings from the PACIFIC trial have made a significant impact on the treatment of patients with unresectable stage III non–small cell lung cancer, especially in light of the history of treatment options in this setting.

Dr. Decker on Current Role of Radiation in NSCLC

January 28th 2019

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses the current role of radiation therapy in the treatment of patients with non–small cell lung cancer.

Brahmer Provides a Glimpse of Future Immunotherapeutics in NSCLC

January 28th 2019

Despite the rapidly expanding therapeutic options available in immunotherapy for patients with non-small cell lung cancer, there are still a number of drawbacks to treatment, explaining why not all patients respond to current treatment options.

Dr. Jahanzeb on Eligibility Criteria for Immunotherapy Trials in NSCLC

January 28th 2019

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the eligibility criteria for immunotherapy trials in non–small cell lung cancer.

Targeted Agents Show Promise Against Emerging Oncogenic Drivers in NSCLC

January 28th 2019

Data on many new treatment options have come forward over the past year highlighting the potential to treat more emerging oncogenic drivers impacting smaller subsets of patients with non–small cell lung cancer.

Surgery Maintains Role in Rapidly Advancing Lung Cancer Treatment Paradigm

January 28th 2019

Eric Vallieres, MD, highlights the technological advances of lung cancer surgery and how this impacts the outlook for patients who are candidates for it.

Dr. Wakelee Discusses Current State of Treatment in NSCLC

January 27th 2019

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses the current state of treatment in patients with non–small cell lung cancer.

Dr. Goldberg Discusses Treatment Approaches for Mesothelioma

January 27th 2019

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses traditional and emerging treatment approaches for patients with mesothelioma.

Treatment Options Expand for ROS1, BRAF, and NTRK Alterations in NSCLC

January 27th 2019

A growing focus on smaller oncogenic drivers in lung cancer has opened up new treatment options and many potential drugs in development for patients with less common alterations.

EGFR-Targeted Activity Helps Differentiation Between TKIs in NSCLC

January 27th 2019

The treatment paradigm for EGFR-mutant non–small cell lung cancer has grown significantly with many EGFR TKIs now available to treat patients with this disease.

Lilenbaum Examines EGFR+ NSCLC Advancements and Potential Role of Immunotherapy

January 27th 2019

Rogerio Lilenbaum, MD, highlights the current treatment approaches for patients with EGFR-positive non–small cell lung cancer and shed light on the potential for immunotherapy in the space.

Dr. Brahmer on Managing Immune-Related AEs in Lung Cancer

January 26th 2019

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses managing immune-related adverse events in lung cancer.

Dr. Garon on Potential for Immunotherapy in EGFR+ NSCLC

January 26th 2019

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the potential for immunotherapy in the treatment of patients with EGFR-positive non–small cell lung cancer.

Naidoo Discusses Advances in the Management of Immunotherapy-Related AEs

March 13th 2018

Jarushka Naidoo, MBBCh, discusses some of the most commonly seen immune-related adverse events in patients with lung cancer and how to manage them.

Dr. Lopes Discusses the Importance of Addressing Financial Toxicity in Lung Cancer

March 13th 2018

Gilberto Lopes Jr, MD, a medical director for International Programs at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the important of addressing financial toxicity during the 5th Annual Miami Lung Cancer Conference.